Back to top
more

Electromed (ELMD)

(Delayed Data from AMEX)

$18.65 USD

18.65
27,778

+0.22 (1.19%)

Updated Aug 7, 2025 03:50 PM ET

After-Market: $18.83 +0.18 (0.97%) 7:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Globus Medical (GMED) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Globus Medical (GMED) delivered earnings and revenue surprises of +13.16% and +0.49%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here is Why Growth Investors Should Buy Electromed (ELMD) Now

by Zacks Equity Research

Electromed (ELMD) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

InspireMD (NSPR) delivered earnings and revenue surprises of -29.41% and 9.21%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Si-Bone (SIBN) delivered earnings and revenue surprises of 37.50% and 5.21%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

PROCEPT BioRobotics (PRCT) delivered earnings and revenue surprises of 8.16% and 5.77%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Electromed, Inc. (ELMD) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Electromed, Inc. (ELMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Bears are Losing Control Over Electromed, Inc. (ELMD), Here's Why It's a 'Buy' Now

by Zacks Equity Research

Electromed, Inc. (ELMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Equity Research

Electromed, Inc. (ELMD) Lags Q1 Earnings Estimates

by Zacks Equity Research

Electromed, Inc. (ELMD) delivered earnings and revenue surprises of -16.67% and 11.12%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Electromed, Inc. (ELMD) Reports Next Week: What Awaits?

by Zacks Equity Research

Electromed, Inc. (ELMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Electromed, Inc. (ELMD) Q4 Earnings Meet Estimates

by Zacks Equity Research

Electromed, Inc. (ELMD) delivered earnings and revenue surprises of 0.00% and 1.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Electromed, Inc. (ELMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Electromed, Inc. (ELMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Alcon (ALC) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Continued strength in the Surgical segment and new launches under Vision Care segment are likely to have driven growth in the second quarter for Alcon (ALC).

Zacks Equity Research

New Strong Sell Stocks for June 3rd

by Zacks Equity Research

ADSK, BNR, NET, ELMD, and POLY have been added to the Zacks Rank #5 (Strong Sell) List on June 3, 2021

Zacks Equity Research

New Strong Sell Stocks for May 13th

by Zacks Equity Research

PRTS, CIGI, ELMD, LLY, and TTWO have been added to the Zacks Rank #5 (Strong Sell) List on May 13, 2021

Zacks Equity Research

Earnings Preview: Electromed, Inc. (ELMD) Q3 Earnings Expected to Decline

by Zacks Equity Research

Electromed, Inc. (ELMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Varian Medical (VAR) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Varian Medical (VAR) is optimistic about its prospective acquisitions and strength in Proton Therapy segment.

Zacks Equity Research

Electromed, Inc. (ELMD) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Electromed, Inc. (ELMD) delivered earnings and revenue surprises of 225.00% and 15.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Electromed, Inc. (ELMD) Q2 Earnings Expected to Decline

by Zacks Equity Research

Electromed, Inc. (ELMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Electromed Enters Oversold Territory

by Zacks Equity Research

Electromed has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Zacks Equity Research

Electromed Enters Oversold Territory

by Zacks Equity Research

Electromed has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Zacks Equity Research

The Zacks Analyst Blog Highlights: TVTY, NXGN, ELMD and FMS

by Zacks Equity Research

The Zacks Analyst Blog Highlights: TVTY, NXGN, ELMD and FMS

Debanjana Dey headshot

4 MedTech Growth Stocks With Strong ROE to Buy Amid Coronavirus

by Debanjana Dey

Here are some MedTech growth stocks which might be solid investment options for profit-maximization amid the coronavirus-led market mayhem.

Zacks Equity Research

Zacks.com featured highlights include: Vista Outdoor, 21Vianet, Electromed and GAIN Capital

by Zacks Equity Research

Zacks.com featured highlights include: Vista Outdoor, 21Vianet, Electromed and GAIN Capital

Nitish Marwah headshot

4 Breakout Stocks for Explosive Returns

by Nitish Marwah

In order to select the right breakout stock one has to first calculate its support and resistance level.

Sejuti Banerjea headshot

5 Themes (& Picks) for Coronavirus Investing

by Sejuti Banerjea

Coronavirus is going to be around for a while, so let's use it to define our investment strategies.